Discover the latest news from the Pulmonary Hypertension, including advocacy updates, research articles and event coverage.
While the world seems to have moved on from the pandemic, many in the pulmonary hypertension community are trying to catch up. Because PH makes people more vulnerable to serious COVID side effects, the community remains cautious about how to proceed. This year, the Pulmonary Hypertension Association wants to help you transition from pandemic mode to more familiar routines.
The Pulmonary Hypertension Association is accepting applications for a new grant to support junior pulmonary hypertension researchers. Apply now, or spread the word about PHA’s Early Career Mentored Scientist Award. The one-year grant covers up to $65,000 for PH-related research projects that have been favorably reviewed but not funded by the National Institutes of Health. Apply by March 20.
The Pulmonary Hypertension Association seeks empathetic volunteers eager to support their peers in the pulmonary hypertension community. As the year begins, we have several volunteer shifts for our in-person, phone and online support services. Tiffany Gunville of Minot, North Dakota, encourages others to get involved. “Others were there for me. Now it’s my turn to give back.”
Twelve years after her pulmonary hypertension diagnosis, Marcie McGregor credits her faith in God, her doctors and the Pulmonary Hypertension Association (PHA) for where she is today.
Diagnosis & treatment
Allison was diagnosed with pulmonary hypertension (PH) as a senior in high school. Elizabeth is a pediatric nurse practitioner at UCSF Benioff Children’s Hospital.
Get involved
Donna Sparks combats a progressive life-threatening lung disease with courage, conviction and compassion — for herself and others who share her fight.
Diagnosis & treatment | Living with PH
Ralinepag met a primary goal to delay disease progression in a Phase 3 study, United Therapeutics announced. The study met several secondary goals, including six-minute walk distance.
Read morePulmovant has completed enrollment for its Phase 2 PHocus clinical trial to evaluate a once-daily inhaled treatment for PH-ILD. Mosliciguat helps widen blood vessels and could have anti-inflammatory and anti-fibrotic properties.
Read moreGossamer Bio’s Phase 3 seralutinib trial narrowly missed its primary endpoint goal to show improved six-minute walk distance at week 24, according to its news release. An unexpectedly large improvement in walk distance in the placebo group appeared in part to influence the outcome, Gossamer says. The company noted encouraging findings in key secondary goals, including reductions in NT-proBNP, improvements in clinical status and lower risk scores. The study also showed meaningful treatment effects in patients with intermediate and high-risk PH, Gossamer explains in a document for patients (pdf).
Read more
